Review



recombinant human tnfsf13 hek293 expressed protein  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems recombinant human tnfsf13 hek293 expressed protein
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Recombinant Human Tnfsf13 Hek293 Expressed Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)+Protein/pmc13038214-242-9-16
    Average 94 stars, based on 13 article reviews
    recombinant human tnfsf13 hek293 expressed protein - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics"

    Article Title: TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI186032

    ( A ) ELISA for secreted TNFSF13 in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Figure Legend Snippet: ( A ) ELISA for secreted TNFSF13 in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Control, Variant Assay, RNAscope, Immunostaining, Derivative Assay

    Percentage of FAS + and HVEM + cells by flow cytometry at day 7 after seeding in ( A ) colonoids ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant) or ( B ) iPSC-organoids ( n = 3 passages per line). ( C ) Representative Western blot for FAS from coimmunoprecipitation supernatant in control and VEO-IBD colonoids at day 7. TNFSF13 antibody used for capture. Protein ladder lane (M) not shown in overlay ( n ≥ 4 patient lines for control and VEO-IBD). ( D ) SPR binding analyses of FASL-FAS (upper) and TNFSF13-FAS (lower) interactions at various concentrations ( n = 3 independent experiments). ( E ) Costaining of TNFSF13 and FAS RNAscope probes in control colonoids at day 7. Arrows indicate coexpression (scale bar: 100 μm; n = 3 experiments). ( F ) Co staining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( G ) Costaining of TNFSF13 and FAS RNAscope probes with FABP2 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( H and I ) Percentage of EdU+ cells in control colonoids (left) or WT iPSC-organoids (right) at day 7 following treatment with ( H ) IgG or FAS neutralizing antibody (nFAS) or ( I ) IgG or recombinant human FAS ligand (rFASL). Two-way ANOVA with multiple comparisons for ( A and B ); 2-tailed Student’s t test for ( H and I ). P values shown unless P > 0.05.
    Figure Legend Snippet: Percentage of FAS + and HVEM + cells by flow cytometry at day 7 after seeding in ( A ) colonoids ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant) or ( B ) iPSC-organoids ( n = 3 passages per line). ( C ) Representative Western blot for FAS from coimmunoprecipitation supernatant in control and VEO-IBD colonoids at day 7. TNFSF13 antibody used for capture. Protein ladder lane (M) not shown in overlay ( n ≥ 4 patient lines for control and VEO-IBD). ( D ) SPR binding analyses of FASL-FAS (upper) and TNFSF13-FAS (lower) interactions at various concentrations ( n = 3 independent experiments). ( E ) Costaining of TNFSF13 and FAS RNAscope probes in control colonoids at day 7. Arrows indicate coexpression (scale bar: 100 μm; n = 3 experiments). ( F ) Co staining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( G ) Costaining of TNFSF13 and FAS RNAscope probes with FABP2 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( H and I ) Percentage of EdU+ cells in control colonoids (left) or WT iPSC-organoids (right) at day 7 following treatment with ( H ) IgG or FAS neutralizing antibody (nFAS) or ( I ) IgG or recombinant human FAS ligand (rFASL). Two-way ANOVA with multiple comparisons for ( A and B ); 2-tailed Student’s t test for ( H and I ). P values shown unless P > 0.05.

    Techniques Used: Flow Cytometry, Control, Variant Assay, Western Blot, Binding Assay, RNAscope, Staining, Recombinant

    ( A ) UMAP showing the expression pattern of TNFSF13 and FAS in scRNA-seq data from human tissue–derived colonoids. ( n = 2 lines of colonoids from 2 different patients for control and VEO-IBD, n = 2 independent passages of colonoids for variant.) Dot plot indicating the relative expression pattern of selected genes of TNFSF13 family and related receptors and enterocyte markers among annotated clusters for human colonoids scRNA-seq data. ( B ) Dot plot with relative expression of top 5 changed genes for each annotated cluster for scRNA-seq datasets in human colonoids. ( C ) Color scale indicates group with higher percentage of cells within a given cluster in each comparison. The color indicates the condition with higher percentage of a cluster in each pairwise comparison. ( D ) Dot plot with relative expression of selected genes of TNFSF13 family and related receptors and enterocyte markers among control, VEO-IBD and variants in human colonoids. ( E ) qPCR for ALDOB in colonoids on d7 after seeding. n = 3 lines of colonoids from 3 different patients for control and VEO-IBD, n = 3 passages of colonoids for variant. One-way ANOVA (with multiple comparisons) was used for statistical analysis. ( F ) Representative IF images for FABP2 and E-cadherin in human colonoids. White arrows denote FABP2 + cells. Scale bar: 50 μm. P values are shown on bar graphs unless P > 0.05.
    Figure Legend Snippet: ( A ) UMAP showing the expression pattern of TNFSF13 and FAS in scRNA-seq data from human tissue–derived colonoids. ( n = 2 lines of colonoids from 2 different patients for control and VEO-IBD, n = 2 independent passages of colonoids for variant.) Dot plot indicating the relative expression pattern of selected genes of TNFSF13 family and related receptors and enterocyte markers among annotated clusters for human colonoids scRNA-seq data. ( B ) Dot plot with relative expression of top 5 changed genes for each annotated cluster for scRNA-seq datasets in human colonoids. ( C ) Color scale indicates group with higher percentage of cells within a given cluster in each comparison. The color indicates the condition with higher percentage of a cluster in each pairwise comparison. ( D ) Dot plot with relative expression of selected genes of TNFSF13 family and related receptors and enterocyte markers among control, VEO-IBD and variants in human colonoids. ( E ) qPCR for ALDOB in colonoids on d7 after seeding. n = 3 lines of colonoids from 3 different patients for control and VEO-IBD, n = 3 passages of colonoids for variant. One-way ANOVA (with multiple comparisons) was used for statistical analysis. ( F ) Representative IF images for FABP2 and E-cadherin in human colonoids. White arrows denote FABP2 + cells. Scale bar: 50 μm. P values are shown on bar graphs unless P > 0.05.

    Techniques Used: Expressing, Derivative Assay, Control, Variant Assay, Comparison

    Related Articles

    Recombinant:

    Article Title: Gene Expression Analysis Implicates a Death Receptor Pathway in Schizophrenia Pathology
    Article Snippet: .. Human recombinant TNFSF13 (Catalogue Number 884-AP, RD Systems) was added (in 50% fresh media) at final concentrations of 0, 1 and 100 ng TNFSF13/mL media 48, 24 and 12 hours prior to pH determination. .. At time zero (48 hours after assay commencement), all wells were quickly washed in 37°C PBS, pH 7.4 followed by incubation for 30 minutes at 37°C with 10 μM 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM: Invitrogen Life Sciences, Australia) in PBS.



    Similar Products

    recombinant human tnfsf13 hek293 expressed protein  (R&D Systems)
    94
    R&D Systems recombinant human tnfsf13 hek293 expressed protein
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Recombinant Human Tnfsf13 Hek293 Expressed Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)+Protein/pmc13038214-242-9-16
    Average 94 stars, based on 1 article reviews
    recombinant human tnfsf13 hek293 expressed protein - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant april protein  (R&D Systems)
    94
    R&D Systems recombinant april protein
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Recombinant April Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)+Protein/pmc13006415-566-23-26
    Average 94 stars, based on 1 article reviews
    recombinant april protein - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    april  (R&D Systems)
    94
    R&D Systems april
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    April, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)+Protein/pmc12901160-271-6-9
    Average 94 stars, based on 1 article reviews
    april - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    il 6  (R&D Systems)
    94
    R&D Systems il 6
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)+Protein/pm41680132-355-2-7
    Average 94 stars, based on 1 article reviews
    il 6 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    human april protein  (R&D Systems)
    94
    R&D Systems human april protein
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Human April Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)+Protein/bio_rxiv__64898__2026__01__16__699674-60-30-34
    Average 94 stars, based on 1 article reviews
    human april protein - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    recombinant human april  (R&D Systems)
    93
    R&D Systems recombinant human april
    ( A ) ELISA for secreted <t>TNFSF13</t> in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.
    Recombinant Human April, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+recombinant+tnfsf13/Recombinant+Human+APRIL%2FTNFSF13+(HEK293-expressed)%2C+CF/us12466893-997-11-15
    Average 93 stars, based on 1 article reviews
    recombinant human april - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) ELISA for secreted TNFSF13 in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.

    Journal: The Journal of Clinical Investigation

    Article Title: TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics

    doi: 10.1172/JCI186032

    Figure Lengend Snippet: ( A ) ELISA for secreted TNFSF13 in colonoid conditioned media ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant). ( B ) Representative TNFSF13 RNAscope in colonoids from control and variant participants (scale bar: 50 μm; n = 3 patient lines for control; n = 3 passages for variant). ( C ) Costaining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in colon biopsies. Arrows indicate cells accumulated outside epithelial crypts ( n = 3 patients for control; n = 3 tissue blocks for variant). ( D ) Representative images of colonoid formation assays at day 6 after seeding (scale bar: 300 μm). ( E ) Quantification of newly formed colonoids by size at day 6. Each passage included 2 technical replicates ( n = 4 patient lines for control and VEO-IBD; n = 4 passages for variant). ( F ) TNFSF13 and FAS RNAscope with E-cadherin immunostaining in WT and variant iPSC-derived colon organoids at day 7 (scale bar: 50 μm; n = 3 passages). ( G ) Representative colonoid formation in WT and variant iPSC-derived organoids at day 9 (scale bar: 400 μm; n = 3 passages, each with ≥ 2 technical replicates). ( H ) Quantification of colonoid formation rate and area at day 9. Colonoid size calculated by maximum vertical projection area. ( I and J ) Percentage of EdU + cells following IgG or TNFSF13 neutralizing antibody (nTNFSF13) treatment in ( I ) control tissue–derived colonoids ( n = 3 patient lines) or ( J ) WT iPSC-organoids at day 7 ( n = 3 passages). 2-way ANOVA with multiple comparisons was used for ( A and E ); 2-tailed Student’s t test for ( H – J ). P values shown on graphs unless P > 0.05.

    Article Snippet: To evaluate the function of TNFSF13 in B cells, recombinant Human TNFSF13 (HEK293-expressed) protein (Cat #5860-AP-010, R&D Systems, Minnesota, USA) at a varying concentration gradient (0, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 1.5, 2 μg/mL) was added at 4h post plating.

    Techniques: Enzyme-linked Immunosorbent Assay, Control, Variant Assay, RNAscope, Immunostaining, Derivative Assay

    Percentage of FAS + and HVEM + cells by flow cytometry at day 7 after seeding in ( A ) colonoids ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant) or ( B ) iPSC-organoids ( n = 3 passages per line). ( C ) Representative Western blot for FAS from coimmunoprecipitation supernatant in control and VEO-IBD colonoids at day 7. TNFSF13 antibody used for capture. Protein ladder lane (M) not shown in overlay ( n ≥ 4 patient lines for control and VEO-IBD). ( D ) SPR binding analyses of FASL-FAS (upper) and TNFSF13-FAS (lower) interactions at various concentrations ( n = 3 independent experiments). ( E ) Costaining of TNFSF13 and FAS RNAscope probes in control colonoids at day 7. Arrows indicate coexpression (scale bar: 100 μm; n = 3 experiments). ( F ) Co staining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( G ) Costaining of TNFSF13 and FAS RNAscope probes with FABP2 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( H and I ) Percentage of EdU+ cells in control colonoids (left) or WT iPSC-organoids (right) at day 7 following treatment with ( H ) IgG or FAS neutralizing antibody (nFAS) or ( I ) IgG or recombinant human FAS ligand (rFASL). Two-way ANOVA with multiple comparisons for ( A and B ); 2-tailed Student’s t test for ( H and I ). P values shown unless P > 0.05.

    Journal: The Journal of Clinical Investigation

    Article Title: TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics

    doi: 10.1172/JCI186032

    Figure Lengend Snippet: Percentage of FAS + and HVEM + cells by flow cytometry at day 7 after seeding in ( A ) colonoids ( n = 3 patient lines for control and VEO-IBD; n = 3 passages for variant) or ( B ) iPSC-organoids ( n = 3 passages per line). ( C ) Representative Western blot for FAS from coimmunoprecipitation supernatant in control and VEO-IBD colonoids at day 7. TNFSF13 antibody used for capture. Protein ladder lane (M) not shown in overlay ( n ≥ 4 patient lines for control and VEO-IBD). ( D ) SPR binding analyses of FASL-FAS (upper) and TNFSF13-FAS (lower) interactions at various concentrations ( n = 3 independent experiments). ( E ) Costaining of TNFSF13 and FAS RNAscope probes in control colonoids at day 7. Arrows indicate coexpression (scale bar: 100 μm; n = 3 experiments). ( F ) Co staining of TNFSF13 and FAS RNAscope probes with Ki67 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( G ) Costaining of TNFSF13 and FAS RNAscope probes with FABP2 antibody in control colonoids at day 7. Arrows indicate triple-positive cells (scale bar: 100 μm; n = 3 experiments). ( H and I ) Percentage of EdU+ cells in control colonoids (left) or WT iPSC-organoids (right) at day 7 following treatment with ( H ) IgG or FAS neutralizing antibody (nFAS) or ( I ) IgG or recombinant human FAS ligand (rFASL). Two-way ANOVA with multiple comparisons for ( A and B ); 2-tailed Student’s t test for ( H and I ). P values shown unless P > 0.05.

    Article Snippet: To evaluate the function of TNFSF13 in B cells, recombinant Human TNFSF13 (HEK293-expressed) protein (Cat #5860-AP-010, R&D Systems, Minnesota, USA) at a varying concentration gradient (0, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 1.5, 2 μg/mL) was added at 4h post plating.

    Techniques: Flow Cytometry, Control, Variant Assay, Western Blot, Binding Assay, RNAscope, Staining, Recombinant

    ( A ) UMAP showing the expression pattern of TNFSF13 and FAS in scRNA-seq data from human tissue–derived colonoids. ( n = 2 lines of colonoids from 2 different patients for control and VEO-IBD, n = 2 independent passages of colonoids for variant.) Dot plot indicating the relative expression pattern of selected genes of TNFSF13 family and related receptors and enterocyte markers among annotated clusters for human colonoids scRNA-seq data. ( B ) Dot plot with relative expression of top 5 changed genes for each annotated cluster for scRNA-seq datasets in human colonoids. ( C ) Color scale indicates group with higher percentage of cells within a given cluster in each comparison. The color indicates the condition with higher percentage of a cluster in each pairwise comparison. ( D ) Dot plot with relative expression of selected genes of TNFSF13 family and related receptors and enterocyte markers among control, VEO-IBD and variants in human colonoids. ( E ) qPCR for ALDOB in colonoids on d7 after seeding. n = 3 lines of colonoids from 3 different patients for control and VEO-IBD, n = 3 passages of colonoids for variant. One-way ANOVA (with multiple comparisons) was used for statistical analysis. ( F ) Representative IF images for FABP2 and E-cadherin in human colonoids. White arrows denote FABP2 + cells. Scale bar: 50 μm. P values are shown on bar graphs unless P > 0.05.

    Journal: The Journal of Clinical Investigation

    Article Title: TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics

    doi: 10.1172/JCI186032

    Figure Lengend Snippet: ( A ) UMAP showing the expression pattern of TNFSF13 and FAS in scRNA-seq data from human tissue–derived colonoids. ( n = 2 lines of colonoids from 2 different patients for control and VEO-IBD, n = 2 independent passages of colonoids for variant.) Dot plot indicating the relative expression pattern of selected genes of TNFSF13 family and related receptors and enterocyte markers among annotated clusters for human colonoids scRNA-seq data. ( B ) Dot plot with relative expression of top 5 changed genes for each annotated cluster for scRNA-seq datasets in human colonoids. ( C ) Color scale indicates group with higher percentage of cells within a given cluster in each comparison. The color indicates the condition with higher percentage of a cluster in each pairwise comparison. ( D ) Dot plot with relative expression of selected genes of TNFSF13 family and related receptors and enterocyte markers among control, VEO-IBD and variants in human colonoids. ( E ) qPCR for ALDOB in colonoids on d7 after seeding. n = 3 lines of colonoids from 3 different patients for control and VEO-IBD, n = 3 passages of colonoids for variant. One-way ANOVA (with multiple comparisons) was used for statistical analysis. ( F ) Representative IF images for FABP2 and E-cadherin in human colonoids. White arrows denote FABP2 + cells. Scale bar: 50 μm. P values are shown on bar graphs unless P > 0.05.

    Article Snippet: To evaluate the function of TNFSF13 in B cells, recombinant Human TNFSF13 (HEK293-expressed) protein (Cat #5860-AP-010, R&D Systems, Minnesota, USA) at a varying concentration gradient (0, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 1.5, 2 μg/mL) was added at 4h post plating.

    Techniques: Expressing, Derivative Assay, Control, Variant Assay, Comparison